다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Journal of hepatology : the journal of the European Association for the Study of the Liver, v.33 no.2, 2000년, pp.329 - 332
Fontana, R.J. , Lok, A.S.F.
초록이 없습니다.
Semin Liver Dis Margolis 11 84 1991 10.1055/s-2008-1040427 Hepatitis B: evolving epidemiology and implications for control
Clin Microbiol Rev Mahoney 12 351 1999 10.1128/CMR.12.2.351 Update on diagnosis, management, and prevention of hepatitis B virus infection
Br J Surg Pugh 60 646 1973 10.1002/bjs.1800600817 Transection of the esophagus for bleeding esophageal varices
Hepatology Christensen 4 430 1984 10.1002/hep.1840040313 Prognostic value of Child-Turcotte cirteria in medically treated cirrhosis
Ann Intern Med Weissberg 101 613 1984 10.7326/0003-4819-101-5-613 Survival in chronic hepatitis B. An analysis of 379 patients
Gastroenterology de Jongh 103 1630 1992 10.1016/0016-5085(92)91188-A Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver
Hepatology Donato 26 579 1997 10.1002/hep.510260308 Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case-control study in Italy
J Infect Dis Fattovich 155 931 1987 10.1093/infdis/155.5.931 Influence of hepatitis Delta virus infection on progression to cirrhosis in chronic hepatitis B
J Hepatol Realdi 21 656 1994 10.1016/S0168-8278(94)80115-0 Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis
Hepatology Liaw 13 627 1991 10.1002/hep.1840130403 Incidence, determinants, and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study
N Engl J Med Lee 337 1733 1997 10.1056/NEJM199712113372406 Hepatitis B virus infection
N Engl J Med Dienstag 341 1256 1999 10.1056/NEJM199910213411702 Lamivudine as initial treatment for chronic hepatitis B in the United States
N Engl J Med Lai 339 61 1998 10.1056/NEJM199807093390201 A one year trial of lamivudine for chronic hepatitis B
Gastroenterolgy Perrillo 109 908 1995 10.1016/0016-5085(95)90401-8 Low dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus
Gastroenterology Hoofnagle 104 1116 1993 10.1016/0016-5085(93)90281-G Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B
Hepatology Tassopoulos 29 889 1999 10.1002/hep.510290321 Efficacy of lamivudine in patients with hepatitis B e antigen-negative/ hepatitis B virus DNA positive (Precore mutant) chronic hepatitis B
Hepatology Schiff 28 388A 1998 A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy
Hepatology Villeneuve 31 207 2000 10.1002/hep.510310130 Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B
Hepatology Perrillo 30 301A 1999 Lamivudine for suppression of viral replication in patients with decompensated chronic hepatitis B
J Hepatol Yao 33 301 2000 10.1016/S0168-8278(00)80371-2 Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection
J Hepatol Kapoor 33 308 2000 10.1016/S0168-8278(00)80372-4 Beneficial effects of lamivudine in hepatitis B virus related decompensated cirrhosis
Transplantation Fontana 67 S16 1999 10.1097/00007890-199904150-00068 Is lamivudine beneficial in HBsAg+ patients awaiting liver transplantation? Experience in 182 North American patients
J Hepatol Leung 30 Suppl 1 59 1999 Three year lamivudine therapy in chronic HBV
Antiviral Therapy Chang 5 Suppl. 1 44 2000 Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV patients treated with lamivudine for four years
Hepatology Melegari 27 628 1998 10.1002/hep.510270243 Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective
J Hepatol Honkoop 26 1393 1997 10.1016/S0168-8278(97)80476-X Lamivudine resistance in immunocompetent chronic hepatitis B
Lancet Bartholomew 349 20 1998 10.1016/S0140-6736(96)02266-0 Hepatitis-B-virus resistance to lamvudine given for recurrent infection after orthotopic liver transplantation
Hepatology Liaw 30 567 1999 10.1002/hep.510300221 Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamvudine therapy
J Hepatol Mutimer 30 715 1999 10.1016/S0168-8278(99)80204-9 High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation
J Infect Dis Mutimer 181 713 2000 10.1086/315238 Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy
J Hepatol de Man 29 669 1998 10.1016/S0168-8278(98)80164-5 The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famiciclovir non-response, followed by lamivudine resistance resulting in graft loss
Hepatology Xiong 28 1669 1998 10.1002/hep.510280629 Mutations in hepatitis B DNA polymerase with resistance to lamvudine do not confer resistance to adefovir in vitro
Gastroenterology Perrillo 116 L0356 1999 In vivo demonstration of sensitivity of YMDD mutants to adefovir
J Infect Dis Gauthier 180 1757 1999 10.1086/315147 Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine
Hepatology Perrillo 29 1581 1999 10.1002/hep.510290507 Multicenter study of lamivudine therapy for hepatitis B after liver transplantation
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.